HUMA · Humacyte, Inc.

Humacyte's Q1 2026 results reflect the challenges of Symvess commercialization, with stable but low revenue overshadowed by gross margin deterioration and persistent operating losses. Revenue held nearly steady at $495K, down just 4.3% from $517K year-over-year, as the business transitions toward product sales following FDA approval and launch. This stability underscores early commercial traction in vascular trauma, though scale remains limited.

Gross profit swung sharply to a -$1.5M loss from $370K profit, yielding a -311.7% margin, as cost of goods sold absorbed manufacturing overhead, royalty expenses, and inventory reserves to net realizable value. Management notes these reflect unused production capacity and obsolescence provisions amid the shift—beginning in 2025—of certain payroll and overhead costs from R&D to inventory and COGS upon product sales. This reclassification explains the profitability pressure, as prior-year gross margins benefited from different inventory dynamics before capitalization post-launch.

Net results flipped to a -$17.6M loss from $39.1M profit, with diluted EPS at -$0.09 versus $0.28. This volatility stems from a sharp drop in other income, net, absent the prior period's non-cash gains from contingent earnout and derivative fair value remeasurements. Such swings are characteristic of post-SPAC biotechs but underscore earnings unpredictability.

Cash flow showed resilience, with operating use narrowing to -$25.1M from -$28.6M, driven by inventory changes as commercialization alters working capital patterns. Free cash flow was -$25.3M after $175K capex, down from $228K prior year. Management emphasizes that future capital needs hinge on development scope, manufacturing scale, and Symvess sales momentum. Expenses are expected to rise supporting infrastructure, public company costs, and international approvals, necessitating funding to bridge toward revenue inflection.